Bivictrix Therapeutics PLC on Wednesday said it identified a development lead for its BVX001 programme, which aims to formulate the next-generation of antibody drug conjugates.
The Cheshire, England-based biotechnology company focusing on cancer therapies said the lead was developed using its proprietary Bi-Cygni approach. The lead was selected based on promising in vitro potency and cancer cell selectivity data, alongside encouraging data reported from a panel of ex-vivo safety assays using healthy human cells.
Ex-vivo medical procedures use tissue from an organism in an external environment, while in-vivo procedures refers to work performed in a living organism.
Bivictrix said the lead would now be taken into a panel of in-vivo models. These will include models of acute myeloid leukaemia to investigate the optimum dose of the molecule, as well as safety models to provide indicative safety data.
The results will support manufacturing preparations and guide future clinical trials.
‘This marks a significant step forward towards progressing this programme to the clinic, where we hope to deliver key outcomes for patients who currently have limited options. This announcement also comes at a time when interest in the antibody drug conjugates sector is on the rise with over 12 deals and partnerships announced this year alone,’ said Chief Executive Officer Tiffany Thorn.
Shares in Bivictrix were up 21% to 18.70 pence each in London on Wednesday morning.
Copyright 2022 Alliance News Ltd. All Rights Reserved.
